Abstract Number: PB0853
Meeting: ISTH 2021 Congress
Background: Many pharmacological drugs of different structures (carbohydrate, peptide, protein) with antiplatelet action are known. Directed influence of these agents may to reduce pathologically increased platelet aggregation. Earlier it was shown that regulatory glyproline peptides exhibit anticoagulant and antiplatelet effects in the organism. Also, the amino acid arginine reduces the possibility of blood clots improving endothelial function and reducing platelet aggregation.
Aims: To study the antiplatelet effects of arginine-containing glyproline peptides and acetylsalicylic acid (aspirin) in a comparative aspect.
Methods: All experiments were conducted on male Wistar rats in accordance with the Helsinki Declaration of the world Medical Association on humane treatment of animals and the Geneva Convention «Internetional Guiding Principals for Biomedical Involving Animals». One of the peptides (100 mkg/kg) Lys-Arg-Arg-Lys-Pro-Gly-Pro (KRRKPGP), Lys-Lys-Arg-Arg-Pro-Gly-Pro (KKRRPGP), Arg-Lys-Lys-Arg-Pro-Gly-Pro (RKKRPGP), Arg-Pro-Gly-Pro (RPGP) and aspirin (1 mg/kg) was administered to rats intragastric for 7 days. Blood for research were collected from the v.jugular 20 h after the last drugs administration. The measurement of platelet aggregation was started upon the addition of 10-6 M ADP in rich platelet blood plasma (Born method).
Results: It was found that 20 h after the last of administration of KRRKPGP, KKRRPGP, RKKRPGP and RPGP, platelet aggregation decreased in rats by 29%, 34%, 49% and 19%, respectively, compared with saline control group (100%). The injection of aspirin lead to platelet aggregation decrease by 24% vs. control. So, RKKRPGP had the most pronounced antiplatelet effects in rat organism.
Conclusions: Thus, the present research showed that the studied drugs have significant antiplatelet effect due to decrease activation of platelet haemostasis due to reduced platelet aggregation. Besides, the antiplatelet effects of the studied peptides are comparable to the action of the well-known agent aspirin. We assume that regulatory arginine-containing glyproline oligopeptides can be attributed to a perspective antiplatelet agents without side effects.
To cite this abstract in AMA style:Grigorjeva M, Obergan T, Shubina T, Lyapina L. Arginine-containing Peptides and Acetylsalicylic Acid: Evaluation of Antiplatelet Effects [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/arginine-containing-peptides-and-acetylsalicylic-acid-evaluation-of-antiplatelet-effects/. Accessed November 27, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/arginine-containing-peptides-and-acetylsalicylic-acid-evaluation-of-antiplatelet-effects/